 RICHMOND, Va.--BUSINESS WIRE--Aditxt, Inc. Nasdaq: ADTX, a biotech innovation company with a mission to improve the health of the immune system, today announced it has closed on a registered direct offering for 11 million announced on August 26, 2021 and funded a bridge loan to its acquisition target, satisfying a key term of the Letter of Intent LOI. Additionally, the Company entered into an agreement with the holder of its outstanding convertible note, whereby the parties agreed to wai 